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Abstract
Purpose of Review To update the current knowledge concerning sleep complaints and breathing disorders in myotonic dystrophy
type 2 (DM2) and to better understand if sleep and breathing symptoms may add a further clinical definition of DM2.
Recent Findings Although DM2 has been poorly evaluated, the most relevant sleep disorders are sleep-disordered breathing
(SDB) (37.5–66.7%) and restless legs syndrome (RLS) (50–60%). Excessive daytime somnolence (EDS) is not consistent with
SDB, and a large percentage of patients with sleep complaints (58–69%) report pain. In addition, respiratory dysfunctions are
reported in 6 to 15% of DM2 patients, albeit few data are available regarding pulmonary restriction, hypoventilation, and non-
invasive ventilation (NIV).
Summary SDB, RLS, and pain may contribute to sleep fragmentation and EDS in DM2. In addition, few studies report
hypoventilation and pulmonary restriction, although there are no studies at all on NIV, except for limited clinical experiences.
These findings suggest performing a careful pulmonary examination and NIV when required. Furthermore, sleep studies and
respiratory evaluation should be recommended if OSA or respiratory muscle dysfunctions are suspected. A large polysomno-
graphic study should be performed to clarify the link between sleep disorders, pain, and sleep disruption in DM2.
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Introduction
Myotonic dystrophies are autosomal dominant genetic disorders
characterized by progressive and multisystemic involvement dis-
orders including myopathy, myotonia and cardiomyopathy, en-
docrine abnormalities, and neuropsychological deficits [1].
Myotonic dystrophy types 1 (DM1) and 2 (DM2) represent the
two clinical, histopathological, and genetic forms of myotonic
dystrophy, although these entities show an overlap in the clinical
features [2]. Both dystrophies are caused by genetic repeat ex-
pansions; DM1, related to a CTG repeat in the DMPK gene [3]
and DM2 to a CCTG repeat expansion in the CNBP gene (also
known as ZNF9) [4]. DM2 resembles adult-onset DM1 with
similar clinical multi-organ involvement (i.e., muscle atrophy,
weakness, myotonia, cardiac arrhythmia, posterior cataract, dia-
betes, cognitive, and psychiatric disturbances), even if there are
significant clinical differences such as proximal muscle involve-
ment, slow and less severe disease progression, later and less
prominent respiratory weakness, and better cognitive condition
[5•, 6]. Also, DM2 shows sex differences, since women more
often have proximal muscle weakness and more severe disease,
whereas men more frequently showmyalgic and pain symptoms
[7••]. Sleep disorders are highly reported in neuromuscular dis-
eases as probable causes of mortality and morbidity [8•].
Persistent and transient sleep hypoxemia due to sleep-
disordered breathing (SDB) may induce cardiovascular and pul-
monary failure. Furthermore, sleep fragmentation and excessive
daytime somnolence (EDS) may impair frailty and may also
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affect psychiatric and cognitive functioning. Although sleep dis-
orders and EDS are highly reported in DM1 [9], DM2 has also
been associated with sleep disturbances and respiratory symp-
toms [10–13]. Firstly, EDS has been mentioned in some anec-
dotal reports of myotonic dystrophy, and this condition was usu-
ally considered secondary to the hypercapnia [14–16].
Obstructive sleep apnea with or without hypoxia and hypercap-
nia, central EDS, rapid eye movement (REM) sleep dysregula-
tion, and periodic limb movements of sleep (PLMS) were de-
scribed in DM1 [17–20]. Sleep and breathing disorders are
scarcely reported in DM2 patients, according to the recent update
on its genetic definition and the low prevalence in some countries
[21]. Nevertheless, recent studies show that SDB, EDS [12, 17,
22, 23], restless legs syndrome (RLS) [13, 24], and REM sleep
disturbances [12, 18] are also present in DM2, although there are
limited polysomnographic data available [12, 25•]. In this narra-
tive review, we aim to highlight the current knowledge regarding
sleep and respiratory disorders in DM2, to better characterize the
clinical spectrum of this type of myotonic dystrophy.
Clinical Presentation and Differential
Diagnosis with DM1
Myotonic dystrophies (DM) are dominantly inherited
multisystemic diseases. Steinert and colleagues described the
“classic” form of myotonic dystrophy in 1909, and it was called
“Steinert’s disease” [26]. The primary clinical manifestations of
DM1 are facial and distal muscleweakness andwasting, together
with grip and percussion myotonia, but a multi-organ involve-
ment is described. In 1992, the gene defect responsible for myo-
tonic dystrophy of Steinert was found to be an abnormal expan-
sion of a CTG repeat in the 3′ untranslated region of myotonic
dystrophy protein kinase gene (DMPK; OMIM 605377) on
chromosome 19q13.3 [27, 28]. The severity of the disease differs
according to the number of CTG repeats and DM1.
Subsequently, it was demonstrated that many of the families
with a similar clinical pattern but without that genetic defect had
an unstable tetranucleotide CCTG repeat expansion in intron 1 of
the nucleic acid-binding protein (CNBP) gene (previously
known as zinc finger 9 gene, ZNF9; OMIM 116955) on chro-
mosome 3q21 [4]. Patients with DM2 share similar core features
of symptoms with DM1, but also have several different clinical
manifestations [26, 29•, 30]. First of all, the onset of DM2 is in
adulthood, without reduction of life expectancies and a congen-
ital form has not been reported. Usually, lower-limb weakness is
the most common symptoms with the involvement of hip flexors
and knee extensors and without the absence of tendon reflexes
(that is common in DM1). Moreover, muscle wasting, distal
weakness, and clinical myotonia could be absent, and muscle
pain is sometimes the dominant symptom. Facial weakness is
almost absent.Multi-organ involvement, similar to that described
inmyotonic dystrophy type 1, also occurs inmyotonic dystrophy
type 2, which is generally considered less severe and frequent
despite the cardiac, respiratory, endocrine, and ocular involve-
ments (see Fig. 1). Since they share the same pathological mech-
anism of DM1, these alterations could be severe and should not
be overlooked. Furthermore, cognitive and behavioral
Fig. 1 Summary of the clinical
features of myotonic dystrophy
type 2 as reported in a large cohort
by Montagnese et al. (Modified
from Montagnese, F., Mondello,
S., Wenninger, S. et al. Assessing
the influence of age and gender
on the phenotype of myotonic
dystrophy type 2. J. Neurol.
2017;264:2472–80, with
permission from Springer
Nature.) [7]
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impairment, above mentioned, could lead to the avoidance of
medical attention [31]. Thus, diagnosis of DM2 could be chal-
lenging, and greater diagnostic delay is not uncommon. The real
prevalence of DM2 is quite heterogeneous in different countries;
Northern European countries (Czech Republic, Finland, and
Germany) manifest a negligible difference between DM1 and
DM2 or even higher prevalence than DM1 [32], whereas in
Asia and sub-Saharan populations, DM2 is virtually absent. On
the other hand, Southern European countries show an estimated
prevalence of about 10% that of DM1 (DM1 9.65 per 100,000
and DM2 0.99 per 100,000) [7••, 33••]. Differential diagnosis
between DM1 and DM2 is thus possible through genetic testing
analysis [26].
Ventilation and Respiratory Muscle
Involvement in DM2
In the physiological condition, the respiratory muscle strength
exceeds the respiratory load thus normal ventilation is pre-
served during rest, exercise, and sleep. In neuromuscular dis-
eases, the muscle weakness is associated with an increased
respiratory load due to the following: (1) inability to have a
useful sigh or to breathe deeply with decreased lung and chest
wall compliance; (2) irreversible degeneration of the joint car-
tilage of the rib cage leading to increased chest wall stiffness;
(3) impaired respiratory muscles contractility due to spinal
deformities such as thoracic scoliosis. With advancing respi-
ratory muscles weakness, airflow decreases and alveolar
hypoventilation occur with an ongoing gradual decline in vital
capacity (VC) and disturbed gas exchange escorted by the
ventilation-perfusion mismatch [34, 35•]. The respiratory in-
volvement in neuromuscular diseases results in a restrictive
defect in which both VC and FEV1 decline before the reduc-
tion in total lung capacity [34, 35•]. A fall of VC in the supine
position of more than 25% concerning the sitting position
indicates a significant diaphragmatic weakness and probably
nocturnal hypoxemia. With further progression of diaphrag-
matic involvement and the continuing decline in VC, patients
become more susceptible to sleep-breathing disorders, which
appear first during REM sleep [35•, 36••]. In DM1, mortality
is mainly due to respiratory problems (failure and pneumonia)
in 43% of patients [37] that were unrelated to significant mus-
cle weakness, but to CTG repeat in the DMPK gene [38].
Mutual interaction between skeletal muscle weakness and
CNS dysfunction may represent the basis of the respiratory
dysfunction [36••,39••]. Irregular breathing patterns, sleep-
breathing disorders, and the finding of reduced ventilatory
response to CO2 independent of respiratory muscle weakness,
all the above symptoms suggest that the central nervous sys-
tem plays an essential role in pathogenesis. It happens fre-
quently that myotonic patients do not relate their symptoms
to respiratory failure as it happens for other symptoms [23,
36••, 39••, 40]. Respiratory parameters are typically moni-
tored upright, while pulmonary function may be better evalu-
ated in supine position, more sensitive at detecting a restrictive
ventilatory pattern [6, 38]. Although non-invasive ventilation
(NIV) for respiratory weakness may potentially represent a
tool to ameliorate survival in myotonic patients, the main lim-
itation is poor adherence and the need for frequent follow-up
[35•, 39••]. Few data are available regarding DM2 patients
and respiratory disorders. Only a minority of both DM1 and
DM2 patients receives a regular evaluation of lung function at
the onset, consequently obtains a pulmonary service referral,
and is on NIV. Thus, a small number of those patients receive
support for secretion management [39••]. Recently, it has been
discussed and proposed a respiratory symptoms checklist
(“RESPICHECK”) for myotonic dystrophies [41]. It includes
nine domains: orthopnea, dyspnea, sleep, headaches, apnea,
cognitive performance, EDS, fatigue, and chest infection
[39••, 41]. Epworth Sleepiness Scale score, correlated with
the RESPICHECK questionnaire score, and pCO2 levels
show a direct correlation, while both the sitting forced vital
capacity and the forced expiratory volume demonstrate an
indirect correlation with this questionnaire in DM1 [41].
Few data are available regarding DM2. The magnitude of
respiratory involvement is reported in two different studies
respectively in 6–15% [39••] and 13% of DM2 patients
[7••]. The last of whom fails in finding any sex difference in
respiratory impairment in DM2 [7••]. Respiratory function has
also been evaluated in a comparative study between DM1 and
DM2 [23]. Orthopnea and morning headache were reported in
13% and 19% of patients with DM2, respectively. Respiratory
symptomswere not correlated with sleep efficiency and wake-
fulness during nocturnal sleep. Lack of symptoms of respira-
tory failure was reported by 25% of DM2 patients versus 16%
of DM1. Sitting VC, supine VC, maximal inspiratory pres-
sure, sniff nasal pressure, and phrenic compound motor action
potential amplitude are lower in DM2 versus controls but less
severely impaired when compared with DM1 patients. Vital
capacity dropped more than 30% on the transition from the
sitting to the supine position in 3/25 (12%) of DM1 patients,
but in none of the DM2 subjects [23]. Lastly, the Serbian
registry of DM2 reported that 10% of patients had lung re-
striction with FVC < 90%, lacking further evaluations of SDB
and respiratory impairment [42].
Sleep-Related Breathing Disorders in DM2
SDB may be explained by the weakness and myotonia of
respiratory muscles and the altered central control of ventila-
tion. Although this hypothesis is not entirely clarified, earlier
studies suggest that reduced respiratory muscle strength itself
does not account for the presence of SDB in myotonic dystro-
phies [17, 18].
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The occurrence of sleep-related breathing disorders (SDB) in
DM2 has been consistently reported and seems to be the most
frequent sleep disorder, but its magnitude has not been evaluated.
However, DM2 patients exhibit EDS, poor sleep quality, de-
creased sleep efficiency, SDB, and diaphragmatic weakness
[7••, 9, 14, 20]. Phrenic CMAP amplitudes, an indicator of dia-
phragm weakness, below normal values have been reported in
DM2 and correlated with respiratory functions and sleep quality
[20]. Only six studies evaluate the impact of SDB in DM2,
including a small population of DM 2 patients, ranging from 5
to 16 [10, 12, 22, 23, 43, 44]. As a whole, 61 patients were
studied with different methods: in-lab polysomnography, ambu-
latory PSG, or at-home cardiorespiratory monitoring (Table 1).
The prevalence of SDB, considering an apnea-hypopnea index
above 5 [45] varies from 37.5 to 66.7% while the prevalence of
moderate-severe SDB (that is, an apnea-hypopnea index above
15), varies from 0 to 50%. The pattern of SDB differs in DM2 as
compared with DM1, since respiratory events are mostly ob-
structive, with a very few observations of central apnea pattern
or a mixed (central and obstructive) one.
Moreover, central events do not differ between DM2 pa-
tients and controls when evaluated at the population level
[23]. Central hypoventilation has not been described in DM2
patients, even if night oxygen desaturation and higher end-
tidal C02 have been reported despite less pronounced than in
the DM1 population [23]. SDB seems to be one of the leading
causes of sleep disruption and EDS in DM2 [12]. The corre-
lation between severity of SDB and EDS is not consistent in
the different papers, but this datum could be related to meth-
odological problems since the majority of the studies evaluate
subjective sleepiness with Epworth Sleepiness Scale, that is
considered as scarcely reliable in this kind of population [19,
25•, 46]. More interestingly, a correlation between SDB and
peripheral neuropathy in DM2 patients was described where
the amplitude of the ulnar and median sensory nerve action
potential (SNAP) was related to nocturnal mean arterial oxy-
gen saturation [44]. The authors propose a two-way mecha-
nism since axonal degeneration may contribute to muscle
weakness and cause nocturnal hypoxemia but also vice versa.
Moreover, in this population, obstructive and central sleep
apneas were correlated with the most of the respiratory param-
eters [10], even if the involvement of the diaphragm and re-
spiratory DM2 phenotype seems to be milder as compared to
DM1.
According to this data, some authors suggest performing
PSG evaluation only in patients with altered pulmonary func-
tion scores, although it is worth underlining that no clear clin-
ical parameters could predict SDB in patients with neuromus-
cular diseases.
Non-invasive Ventilation in DM2
Few data are available regarding the approach of respiratory
disorders and SDB in DM2. The recent 207th ENMC
Workshop on chronic respiratory insufficiency in myotonic
dystrophies has attempted to assess the management of respi-
ratory involvement in the EU, The USA, and Canada and has
agreed and reportedminimum recommendations for screening
and treatment of chronic respiratory insufficiency in myotonic
dystrophies including indications for NIV [39••]. The Italian
experience from NEMO Center reported 8/52 (15%) DM2
patients on NIV. NIVwas prescribed by the following criteria:
nocturnal desaturation (in 87.5% of patients), HCO3− >
30 mEq/L, paCO2 > 45 mmHg, a difference between supine
and sitting FVC > 20%, although the paper did not specify the
differences between DM1 and DM2. The most utilized de-
vices were servo-assistant devices, presso-volumetric, and
Bilevel devices [39••]. The Canadian registry reported 6% of
DM2 patients treated with NIV versus 13% of adult DM1 and
23% of adult congenital DM1. The overall data reported NIV
prescription in 15–20% of DM2 compared to 20–60% of adult
DM1 and 20–40% of congenital DM1 [39••]. Moreover, no
study on ventilation treatment and adherence has been per-
formed. Three DM2 patients presented good clinical response
with CPAP [43]. Thus, the compliance and the impact of ven-
tilation in this population need to be evaluated as well as the
prevalence in a study with a larger population.
Table 1 Sleep-disordered breathing and DM2
Ref. Methods No. of pts OSA (RDI > 5) N (%) Moderate-severe OSA
(RDI > 15) N (%)
Central or mixed pattern N (%)
[22] In-lab PSG 5 3 (60%) 0 (0%) N.A.
[43] In-lab PSG 6 4 (66.7%) 3 (50%) 1 (16.7%)
[12] Amb PSG 16 7 (58.3%) 3 (25%) 1 (6.25%)
[10] CRM 14 6 (42.8%) 2 (14.2%) 2 (14.2%)
[23] In-lab PSG 16 6 (37.5%) N.A. N.A.
[44] CRM 8 3 (37.5%) 0 (0%) 0
In-lab PSG, In-lab polysomnography; Amb PSG, ambulatory polysomnography; CRM, home-based cardiorespiratory monitoring; OSA, obstructive
sleep apnea; RDI, respiratory disease index; N.A., not available
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Sleep Disorders Other than SDB in DM2
& Several sleep disorders—restless legs syndrome (RLS),
EDS, and PLMS—were described both in DM1 and DM2
[17], although few data were specifically reported in DM2
(see Table 2). The first description by Shepard et al. [22]
described RLS in a small uncontrolled series of DM2 pa-
tients. Two out of eight (25%) DM2 patients were affected
by primary RLS since low ferritin levels were found in two
out of four DM2 patients with RLS. Considering the high
mean age (62 years; range, 43–82 years), RLS prevalence
may be considered quite higher than the expected prevalence
in the general elderly population [47]. Besides, DM2 patients
may complain of RLS mimics such as myalgias and pain [5,
48] that may overestimate RLS magnitude in DM2. The
same research group published a further observational
questionnaire-based study [13]. They evaluated 30 DM2 pa-
tients (mean age 63 years) and 44 age and sex-matched
healthy controls and found a higher significant RLS preva-
lence in DM2 compared to healthy controls (18/30 DM2
60% vs. 6/43 HC 14%). These authors concluded that RLS
was the most relevant sleep disorder in DM2 more than
OSAS, which would be represented in DM2 similarly that
in healthy controls. However, the lack of polysomnographic
data may bias these findings probably underestimating SDB
in DM2 [13, 24, 49]. The high prevalence of RLS in DM2
was not confirmed by two polysomnographic controlled
studies [12, 23]. REM sleep dysregulation seems to represent
a sleep feature of both DM1 [20, 50, 51, 52••] and DM2 [12,
17, 25•, 43, 53]. Small case series [43] and single case reports
[53] described REM sleep behavior in OSAS after ventila-
tion by CPAP (1/6 16.6%) and REM sleep without atonia
(RSWA, 1/6 16.6%). Our controlled polysomnographic
study showed a high prevalence of RSWA in DM2 (6/12
50%; 1/6 RSWA with dream-enacting behavior in severe
OSAS, 3/6 RSWA associated with mild to moderate
OSAS) [12]. The actual pathogenesis of RSWA in DM2
patients should be clarified. We may hypothesize that
RSWA may represent a compensatory mechanism against
nocturnal respiratory events [54], and the brainstem and di-
encephalon involvement (i.e., pedunculopontine and
laterodorsal tegmental nuclei) may activate behavioral states
during REM sleep [55].
Fatigue, Pain, and Daytime Somnolence
in DM2
Diurnal sleepiness is defined as “the inability to stay awake
and alert during the major waking episodes of the day,
resulting in periods of irrepressible need for sleep or unintend-
ed lapses into drowsiness or sleep.” The clear distinction be-
tween somnolence and fatigue is still difficult especially in
neuromuscular diseases such as myotonic dystrophies [25•,
56]. Although DM2 represents a less severe form than DM1,
fatigue and EDS are common clinical symptoms of DM2.
Recently, the PRISM-2 study reported fatigue in 89.2% and
EDS in 77% of DM2 patients [57•]. The study was biased by
registry-based design, a female higher prevalence and the lack
of information regarding treatments that may influence sleep,
fatigue or pain. However, it showed a gender effect, being
women more affected by sleep impairment, daytime sleepi-
ness, and fatigue, and a worsening in the quality of life in
DM2 patients complaining of EDS and fatigue. A recent study
confirmed that EDS and fatigue are present in 27% and 47.8%
of DM2 patients respectively [58•]. Finally, a strong
Table 2 Sleep disorders other than SDB in DM2
Ref. Methods No. of DM2 pts Sleep disorders
[11] P, C, subjective scales 29 EDS 6.9%; poor sleep quality 66%
[22] R U sleep complaints, PSG 8* EDS 75%; insomnia 62,5%; RLS 50%
[43] P U sleep complaints, PSG 6 EDS 100%; insomnia 33.3%; RBD in OSAS after CPAP 16.6%;
paradoxical breathing in REM 33.3%; REM sleep without atonia
16.6%; low sleep efficiency—alfa-delta sleep 33.3%
[13] P C subjective scales 30 RLS 60%; EDS 43%; poor sleep quality (PSQI) 66.7%
[12] P C, PSG % subjective scales 12 Sleep disturbance pain-related (PSQI) 58%
EDS (DSS 66.6%; MSLT 33%)
Low sleep efficiency 100%; PLMS 25%; RBD in severe OSAS 8.3%; RSWA 50%
[10] P U subjective scales, CRM 14 Poor sleep quality 42.8%; EDS 14.3%
C, controlled; CPAP, continuous positive airway pressure; CRM, home-based cardiorespiratory monitoring; DM2, myotonic dystrophy type 2; DSS,
daytime sleepiness scale; EDS, excessive daytime somnolence; MSLT, multiple sleep latency test; P, prospective; PLMS, periodic limb movements of
sleep; PSG, polysomnographic study; PSQI, Pittsburgh Sleep Quality Index; R, retrospective; RBD, REM sleep behavior disorder; RSWA, REM sleep
without atonia; U, uncontrolled *5/8 PSG
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association with autoimmune and autoantibodies diseases was
described in DM2 patients [59], and pro-inflammatory condi-
tion may modulate fatigue in neuromuscular disease and sleep
disorders [60, 61, 62••]. Patients affected by myotonic dystro-
phies possibly experienced fatigue, which may be referred to
as EDS [11, 25•]. Pain represents a further overlooked clinical
feature of DM2 [48]. Pain was reported in about 76% of DM2
patients, is mainly exercise or cold temperature-related, and
negatively affects the quality of life [5, 58•, 63, 64••, 65, 66].
The pathophysiology of pain in DM2 is poorly understood.
Peripheral and central sensitizations are likely to play a prom-
inent role in chronic musculoskeletal pain [48, 64••, 67]. The
correlation between sleep and pain in DM2 patients is still
unclear. Tieleman et al. [11] showed that 69% of DM2
patients reported pain as the cause of sleep impairment
(compared with 34% of DM1 patients and 17% of con-
trols) but not of EDS, as evaluated by subjective scales,
and an important effect of myalgia on nocturnal sleep
disruption has been hypothesized. On the other hand,
Lam and colleagues [13] found a high prevalence of
RLS and EDS in DM2, not related to pain and fatigue
in a survey-based study. The first controlled polysomno-
graphic study failed to find significant sleep impairment
in pain complaining patients compared with those not
complaining, although 58% of subjects reported pain-
related sleep disorders through subjective scale
(Pittsburgh Sleep Quality Index) [12].
Conclusion
& Although DM2 has been poorly evaluated, further sleep
studies should be performed to confirm the high preva-
lence of SDB in DM2, to detect its role in EDS, fatigue,
and sleep fragmentation. Furthermore, RLS and RSWA
are frequently reported in DM2 [10, 12, 13, 17, 23, 24,
49]. Few studies report on the frequency of occurrence of
hypoventilation and pulmonary restriction in DM2 pa-
tients; they evaluate it as 6–15% [7••, 39••, 42]. These
findings suggest to perform a careful pulmonary examina-
tion including total and predicted FVC from both the sit-
ting and supine positions [39••]. Furthermore, sleep stud-
ies and respiratory evaluation should be recommended if
OSA or respiratory muscle dysfunctions are suspected.
Nevertheless, there are no studies on ventilation treatment
and adherence, except for the clinical experience reported
in a recent consensus conference [39••]. Nevertheless, a
link between pain and sleep disruption in DM2 [11] has
been hypothesized; the actual role of pain and fatigue in
DM2 patients complaining of EDS, fatigue, and sleep dis-
turbances has not been clarified yet. Thus, a large poly-
somnographic study should be performed to clarify the
clinical phenotype of DM2.
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